Back to all news
OpenEvidence Hits $12B Valuation as Clinical AI Adoption Surges, AI Chatbots Named Top 2026 Healthcare Hazard
OpenEvidence becomes the leading AI platform among U.S. physicians, securing a $12B valuation amid rising concerns about AI chatbot misuse in healthcare.
Key Details
- 1OpenEvidence raises $250M, now valued at $12B, doubling its valuation since October; exceeds $100M annual revenue.
- 2The platform's flagship product supported 18M U.S. physician consultations in December, up from 3M/month a year prior.
- 3Over 40% of U.S. doctors now use OpenEvidence, with 100M+ patients treated via its tools in 2025.
- 4Amazon launches an AI health assistant within its One Medical app, continuing Big Tech's push into clinical AI ecosystems.
- 5ECRI cites 'misuse of AI chatbots' as the #1 health tech hazard for 2026, highlighting serious risks in clinical settings.
Why It Matters
These developments exemplify both the rapid integration and scaling of clinical AI platforms and the urgent need for oversight to mitigate risks—especially as AI becomes more deeply embedded in healthcare. For radiology and imaging AI, these trends spotlight key adoption metrics, the growing ecosystem, and the importance of responsible deployment.
Source
HealthExec
Related News
•HealthExec
UT Austin to Launch $1B+ AI-Driven Medical Center With Major Gift
UT Austin receives $750 million from Michael and Susan Dell toward a $1 billion+ AI-native medical center opening in 2030.
•Radiology Business
MRI AI for Parkinsonian Syndrome Gains FDA De Novo Clearance
Neuropacs Corp.'s MRI AI software earns FDA De Novo classification to assist in Parkinsonian syndrome diagnosis.
•Radiology Business
Lucida Medical Raises $11M for AI-Based Prostate MRI Diagnosis Expansion
Lucida Medical, specializing in AI-assisted prostate cancer diagnosis via MRI, raises $11.4M to drive US FDA approval and platform expansion.